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GENERAL CONSIDERATIONS
The following valvular disorders are considered here in the
context of competitive athletes: mitral stenosis (MS), mitral
regurgitation (MR), aortic stenosis (AS), aortic regurgita-
tion (AR), tricuspid regurgitation (TR), tricuspid stenosis,
and multivalvular disease. Recommendations are also pro-
vided for patients who have undergone valve repair or
replacement.
The diagnosis of valvular heart disease usually can be
made on the basis of the characteristic murmurs and
associated findings on physical examination. Estimation of
the severity of valvular disease is more difficult. In athletes,
where secondary gain in denying symptoms is likely, the
history may be unreliable. In truly asymptomatic patients,
severity can usually be determined from the physical exam-
ination and Doppler echocardiography. Additional testing
is often not necessary, but the electrocardiogram (ECG) and
chest radiograph can also aid in assessing severity, and
radionuclide angiography or cardiac magnetic resonance are
helpful in assessing left ventricular (LV) function when the
echocardiogram is of suboptimal quality.
Doppler echocardiography is the most important diag-
nostic test for valvular heart disease and is generally reliable
in distinguishing the severity of the lesion and assessing
hemodynamics and ventricular compensation. Although
very sensitive in identifying regurgitant jets, quantitation
can be more difficult. Recent guidelines have provided
recommendations for quantifying valvular regurgitation (1).
Only rarely are cardiac catheterization and angiography
necessary to determine the hemodynamic severity of valvular
lesions.
Valvular regurgitation is frequently detected in normal
subjects, including those without murmurs. With pulsed
Doppler echocardiography, TR has been reported in 24% to
96% of normal subjects, MR in 10% to 40%, pulmonic
regurgitation in 18% to 92%, and AR in 0% to 33% (2,3). In
athletes, the prevalence of valvular regurgitation detected by
Doppler is even higher, with at least one regurgitant jet
found in greater than 90% of subjects and triple-valve
regurgitation in 20% (4). The vast majority of these jets
represents a trivial regurgitant volume and is of no clinical
significance.
Although considerable information exists concerning the
natural history, development of symptoms, importance of
LV function, and indications for surgical or catheter-based
intervention in patients with valvular heart disease (5), there
are few data with regard to the rate of progression of the
valvular disease (especially in those exercising vigorously) or
factors that influence the rate of progression. The rate of
progression of aortic stenosis is highly variable among
individuals and difficult to predict (6). Chronic MR may
increase in severity with time but is more likely to do so in
patients who experience a new chordal rupture and flail
mitral leaflet (7). Little is known about the influence of
strenuous exertion on the progression of ventricular dys-
function, especially when that exertion is periodic in nature.
When valvular disease coexists with another cardiovascular
abnormality, such as arrhythmias or coronary artery disease
(CAD), recommendations with regard to eligibility for
sports should be based on the most restrictive of these
guidelines.
The present recommendations with regard to the permitted
level of athletic activity are offered only as guidelines. Physi-
cians with knowledge of an individual athlete, including the
severity of the lesion and the physiological and psychological
response to competition, may liberalize these recommenda-
tions in selected instances. The recommendations are for those
athletes who are asymptomatic, as symptoms will prevent
vigorous exercise in most subjects and, in most circumstances,
symptoms represent an indication for valve replacement or
repair (5). In situations in which the history may be unreliable
(e.g., when secondary gain in denying symptoms is likely),
exercise tolerance testing is useful in confirming normal effort
tolerance and suitability for the proposed athletic activity.
MITRAL STENOSIS
The etiology of MS is almost always rheumatic. Most patients
with significant MS will be sufficiently symptomatic that
participation in competitive sports is not an issue, but patients
with mild-to-moderate MS may be asymptomatic even with
strenuous exercise. Although MS rarely causes sudden death,
exercise (with an increase in heart rate and cardiac output) can
cause sudden marked increases in pulmonary capillary and
pulmonary artery pressures, at times resulting in sudden acute
pulmonary edema (8). Furthermore, the long-term effect of
repeated exertion-related increases in pulmonary artery wedge
and pulmonary artery pressures on the lungs or right ventricle
is unknown. The effect of even periodic strenuous exercise on
the likelihood of developing atrial fibrillation is also not known.
When atrial fibrillation occurs, even patients with mild MS
must be anticoagulated. The aforementioned considerations
must be understood by the patient and the family in consid-
ering participation in strenuous competitive activity. Another
problem associated with MS is systemic embolization, occur-
ring most commonly in the presence of atrial fibrillation, but
there is no evidence that this potential complication is pro-
voked by strenuous exercise.
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Evaluation. Clues regarding the hemodynamic severity of
MS may often be obtained from the history, physical
examination, ECG, and chest radiograph, but accurate
noninvasive assessment of severity requires two-dimensional
and Doppler echocardiography (9). In patients with MS and
minimal or no symptoms who wish to engage in competitive
sports, exercise stress testing should be performed to at least
the level of activity approximating the exercise demands of
the sport, particularly when there is a question as to the
severity of the MS. In addition, pulmonary artery systolic
pressure during exercise can be estimated noninvasively by
Doppler echocardiography and may be helpful in making a
decision as to how much activity is safe, even if the severity
of MS in an individual patient is estimated to be only mild
(5). If this is not practical or possible, then right heart
catheterization with exercise can be performed to measure
the pulmonary capillary wedge pressure and pulmonary
artery pressure.
Hemodynamic severity of MS can be categorized as
follows: mild  mitral valve area greater than 1.5 cm2,
exercise pulmonary artery wedge pressure less than or equal
to 20 mm Hg, or rest pulmonary artery systolic pressure less
than 35 mm Hg; moderate  mitral valve area 1.0 to 1.5
cm2, exercise pulmonary artery wedge pressure less than or
equal to 25 mm Hg, or rest pulmonary artery systolic
pressure less than or equal to 50 mm Hg; severe  mitral
valve area less than 1.0 cm2, exercise pulmonary artery
wedge pressure greater than 25 mm Hg, or rest pulmonary
systolic pressure greater than 50 mm Hg.
Recommendations:
1. Athletes with mild MS (as previously defined) in sinus
rhythm with peak pulmonary artery systolic pressure
during exercise less than 50 mm Hg can participate in
all competitive sports. Athletes with mild MS in atrial
fibrillation, or a history of atrial fibrillation, are dis-
cussed in recommendation 4 below.
2. Athletes with moderate MS (as previously defined),
either in sinus rhythm or in atrial fibrillation, with
peak pulmonary artery systolic pressure during exer-
cise less than 50 mm Hg can participate in low and
moderate static and low and moderate dynamic com-
petitive sports (classes IA, IB, IIA, and IIB [see
Table 1 in Task Force Report 8: Classification of
Sports]).
3. Athletes with severe MS in either sinus rhythm or
atrial fibrillation or those with peak pulmonary artery
pressure greater than 50 mm Hg during exercise
should not participate in any competitive sports.
4. Patients with MS of any severity who are in atrial
fibrillation or have a history of atrial fibrillation, and
who must receive anticoagulation therapy, should not
engage in any competitive sports involving the risk
for bodily contact (see Task Force Report 8: Classi-
fication of Sports) or possible trauma.
MITRAL REGURGITATION
Mitral regurgitation, unlike MS, has a variety of etiologies,
the most common of which is mitral valve prolapse (myx-
omatous mitral valve). Other common causes are rheumatic
heart disease, infective endocarditis, CAD, connective tissue
diseases (such as Marfan syndrome), and dilated cardiomy-
opathy. The recommendations outlined in this section are
for patients with primary valvular MR rather than MR
secondary to CAD or other conditions causing LV dilation
(see Task Force 4: HCM and Other Cardiomyopathies,
Mitral Valve Prolapse, Myocarditis, and Marfan Syndrome,
and Task Force 6: Coronary Artery Disease).
Evaluation. Mitral regurgitation can be detected by the
characteristic physical findings and confirmed by Doppler
echocardiography. The severity of the MR is related to the
magnitude of the regurgitant volume, which results in LV
dilation and increased left atrial pressure. The increased LV
diastolic volume enhances total LV stroke volume enough to
accommodate the regurgitant volume and to maintain the
forward stroke volume within normal limits. The low
impedance presented by regurgitation into the left atrium
unloads the left ventricle during ventricular systole, such
that measures of LV pump function (e.g., ejection fraction)
tend to overestimate true myocardial performance (10).
The severity of chronic MR can be adequately judged by
noninvasive techniques, principally two-dimensional and
Doppler echocardiography. The larger the jet area, and the
wider the jet at its origin above the valve, the more severe
the regurgitation. The entry of the jet into the atrial
appendage or pulmonary vein or systolic reversal of the flow
in pulmonary veins are all indicators of severity. Various
measures of the severity of MR have been described (1,11).
In some patients with eccentric jets or those impinging on
the atrial wall, the assessment may be difficult (1). Gener-
ally, the LV diastolic volume reflects the severity of chronic
MR. However, it should be noted that the upper limit of normal
LV size is increased in the healthy, highly trained athlete. In a
series of elite athletes, echocardiographic LV end-diastolic di-
mensions as high as 66 mm were recorded in women (mean, 48
mm) and up to 70 mm in men (mean, 55 mm) (12). LV
end-diastolic dimensions greater than or equal to 55 mm were
observed in 45% of participants and greater than 60 mm in
14% of participants. Therefore, assessment of LV enlargement in
a highly trained athlete with known or suspected valvular heart
disease must take this issue into consideration. Hence, for
purposes of this discussion, an LV end-diastolic dimension
greater than 60 mm is considered likely to represent the
effects of LV volume overload due to valvular disease and
not per se to physiologically based exercise training.
Patients with chronic MR should be followed longitudi-
nally with serial echocardiograms (5). A decrease in ejection
fraction and/or increase in end-systolic volume with time is
a helpful marker of declining LV function and an indication
of having reached the limits of cardiac compensation.
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Effects of exercise. In general, exercise produces no signifi-
cant change or a mild decrease in the regurgitant fraction
because of reduced systemic vascular resistance. However,
patients with elevation of heart rate (increased systolic ejection
time per min) or blood pressure with exercise may manifest
marked increases in regurgitant volume and pulmonary capil-
lary pressures. Hence, static exercise that increases arterial
pressure is potentially deleterious. Ejection fraction usually
does not change or decreases slightly with exercise, although
the ejection fraction response may be completely normal in
young, asymptomatic subjects.
The etiology of MR may be important in making recom-
mendations concerning heavy physical activity. In patients with
MR secondary to previous infective endocarditis or ruptured
chordae, the valve tissues theoretically could be further dam-
aged or torn by marked sustained increases in LV systolic
pressure.
Recommendations:
1. Athletes with mild to moderate MR who are in sinus
rhythm with normal LV size and function and with
normal pulmonary artery pressures can participate in
all competitive sports.
2. Athletes with mild to moderate MR in sinus rhythm
with normal LV systolic function at rest and mild LV
enlargement (compatible with that which may result
solely from athletic training [less than 60 mm {12}])
can participate in some low and moderate static and
low, moderate, and high dynamic competitive sports
(classes IA, IB, 1C, IIA, IIB, and IIC).
3. Athletes with severe MR and definite LV enlarge-
ment (greater than or equal to 60 mm [12]), pulmo-
nary hypertension, or any degree of LV systolic
dysfunction at rest should not participate in any
competitive sports.
4. Patients in atrial fibrillation or a history of atrial
fibrillation who are receiving long-term anticoagula-
tion should not engage in sports involving any risk
for bodily contact (see Task Force 8: Classification of
Sports) or danger of trauma.
AORTIC STENOSIS
The diagnosis of AS is established by the characteristic
physical findings and two-dimensional and Doppler echo-
cardiography. The three most common etiologies are: 1)
rheumatic, 2) congenital, and 3) calcific or degenerative.
The majority of young adults with AS participating in
competitive athletics have congenital lesions.
Evaluation. Continuous-wave Doppler echocardiography
can reliably estimate the severity of AS, especially in the
presence of normal cardiac output, which is the case in the
great majority of those engaging in competitive sports (13).
Symptoms of dyspnea, syncope, or angina pectoris occur
late in the course of AS (14), and the likelihood of sudden
death increases significantly with the onset of symptoms.
Because even transient symptoms are so important in
marking the onset of increased risk of sudden death, the
physician must be aware that dyspnea, near-syncope, and
even syncope are likely to be unreported in competitive
athletes. Although sudden death is more frequent in symp-
tomatic patients with severe AS, it may also occur in
completely asymptomatic patients (15). When doubt per-
sists with regard to the severity of AS after Doppler study,
or if a patient with mild-to-moderate AS has symptoms,
cardiac catheterization should be performed. Sudden death
is rare with mild AS.
Athletes with a history of syncope, even with mild AS,
should be carefully evaluated by a cardiologist. This should
include assessment of arrhythmias with exercise. Syncope
should be regarded as a possible surrogate for spontaneously
aborted sudden death and should be thoroughly investigated
(see Task Force 7: Arrhythmias).
Severity of AS measured by continuous-wave Doppler
echocardiography (or in those instances previously noted by
cardiac catheterization) is categorized as follows with re-
spect to the calculated aortic valve area: mild  greater than
1.5 cm2; moderate  1.0 to 1.5 cm2; and severe  less than
or equal to 1.0 cm2 (5). This translates roughly (assuming
that athletes have normal cardiac output) to the estimated
mean aortic valve pressure gradient as follows: mild  less
than 25 mm Hg; moderate 25 to 40 mm Hg; and severe
greater than 40 mm Hg (5).
Because AS is often progressive, periodic re-evaluation at
least yearly is necessary and should be performed by a
physician with expertise in cardiology. This reassessment
includes physical examination and Doppler echocardiogra-
phy, but may require cardiac catheterization in selected
patients as previously noted. In addition, Holter monitoring
with intense exercise resembling competition is recom-
mended to detect ventricular arrhythmias in patients with
AS who wish to participate in competitive athletics.
In patients with AS, a markedly elevated cardiac output
or peripheral vascular resistance for sustained periods of
time could result in an exaggerated valvular gradient and a
marked increase in LV systolic pressure. Given these pre-
cautions, the following recommendations can be made.
Recommendations:
1. Athletes with mild AS can participate in all compet-
itive sports, but should undergo serial evaluations of
AS severity on at least an annual basis.
2. Athletes with moderate AS can engage in low-intensity
competitive sports (class IA). Selected athletes may
participate in low and moderate static or low and
moderate dynamic competitive sports (classes IA, IB,
and IIA) if exercise tolerance testing to at least the level
of activity achieved in competition demonstrates satis-
factory exercise capacity without symptoms, ST-
segment depression or ventricular tachyarrhythmias,
and with a normal blood pressure response. Those
1336 Bonow et al. JACC Vol. 45, No. 8, 2005
Task Force 3: Valvular Heart Disease April 19, 2005:1334–40
athletes with supraventricular tachycardia or multiple or
complex ventricular tachyarrhythmias at rest or with
exercise can participate only in low-intensity competi-
tive sports (class IA).
3. Patients with severe AS or symptomatic patients with
moderate AS should not engage in any competitive
sports.
AORTIC REGURGITATION
Aortic regurgitation has multiple etiologies, as any disease
affecting the aortic valve, annulus, or proximal ascending
aorta can result in AR. The common etiologies are: 1)
congenital bicuspid aortic valve; 2) rheumatic heart disease;
3) infective endocarditis; and 4) aortic root diseases, includ-
ing Marfan syndrome, ascending aortic aneurysm, aortic
dissection, systemic hypertension, and rheumatoid spondy-
litis. Aortic regurgitation increases LV diastolic volume and
stroke volume, which may ultimately lead to LV systolic
dysfunction (10). In addition, myocardial oxygen supply/
demand imbalance may develop because of the increased
wall stress, LV hypertrophy, and reduced diastolic blood
pressure (reduced coronary perfusion pressure).
Patients with severe AR may remain asymptomatic and
athletic for many years, but angina pectoris, syncope, and
ventricular arrhythmias ultimately may appear. Sudden
death is rare among asymptomatic patients (less than 0.2%
per year [5]) but can occur.
Evaluation. The hemodynamic severity of AR can be
assessed noninvasively by physical examination (the severity
being reflected by the degree of LV dilation and the
peripheral signs of AR), chest radiography, and echocardi-
ography. As noted previously, the upper limit of normal LV
end-diastolic size is increased in the healthy, highly trained
athlete (12), and this may well affect assessment of LV
enlargement in the setting of AR.
Because of the importance of assessing LV function and
the size of the aortic root and proximal ascending aorta in
determining the etiology of AR, with resulting implications
for athletic participation, evaluation by echocardiography is
essential. Doppler echocardiography is very sensitive in
detecting any degree of AR. Similar to MR, the greatest
difficulty arises in differentiating moderate and severe AR.
Qualitatively, the width of the regurgitant jet and the
proportion of the LV outflow tract occupied by the jet are
related to the severity of the AR, as is the slope velocity
profile of the diastolic jet. The regurgitant volume can also
be measured quantitatively by Doppler methods (1).
The LV function should be assessed serially by two-
dimensional echocardiography (5). Radionuclide angiogra-
phy or cardiac magnetic resonance may be helpful if
echocardiograms are of suboptimal quality. Exercise testing
can be useful in assessing exercise capacity, especially in
those patients having nonspecific or mild symptoms, and it
is recommended that testing be performed to at least the
level of exertion required by the proposed competitive sport.
Holter monitoring with intense exercise resembling compe-
tition is recommended to detect ventricular arrhythmias in
patients who wish to participate in competitive athletics.
Effects of exercise. With exercise, regurgitant volume de-
creases because of the decrease in peripheral vascular resis-
tance that reduces diastolic blood pressure and the decrease
in diastolic filling period that accompanies the increase in
heart rate (16). Because of these changes in preload and
afterload, the failure of the ejection fraction to increase with
exercise is of uncertain significance, and there are insuffi-
cient data with which to use this finding in formulating
recommendations regarding participation in competitive
athletics. There are also no data to define whether severe
increases in physical activity permanently affect the function
of the left ventricle.
For purposes of the following recommendations, hemo-
dynamic severity of AR is graded as follows: mild  absent
to slight peripheral signs of AR, normal LV size; moderate
peripheral signs of AR with mild-to-moderate increases in
LV size with normal systolic function; and severe  periph-
eral signs of AR with severe LV enlargement and/or LV
systolic dysfunction.
Recommendations:
1. Athletes with mild or moderate AR, but with LV
end-diastolic size that is normal or only mildly
increased, consistent with that which may result
solely from athletic training (12), can participate in
all competitive sports. In selected instances, athletes
with AR and moderate LV enlargement (60 to 65
mm) can engage in low and moderate static and low,
moderate, and high dynamic competitive sports
(classes IA, IB, 1C, IIA, IIB, and IIC) if exercise
tolerance testing to at least the level of activity
achieved in competition demonstrates no symptoms
or ventricular arrhythmias. Those with asymptomatic
nonsustained ventricular tachycardia at rest or with
exertion should participate in low-intensity compet-
itive sports only (class IA) (see also Task Force 7:
Arrhythmias).
2. Athletes with severe AR and LV diastolic diameter
greater than 65 mm as well as those with mild or
moderate AR and symptoms (regardless of LV di-
mension) should not participate in any competitive
sports.
3. Those with AR and significant dilation of the prox-
imal ascending aorta (greater than 45 mm) can en-
gage only in low-intensity competitive sports (class
IA). These criteria do not apply to athletes with
Marfan syndrome and AR, in whom the risks of
aortic dissection and rupture are high, and any degree
of aortic dilatation would be sufficient to prohibit
competitive athletics, as discussed in Task Force 4:
HCM and Other Cardiomyopathies, Mitral Valve
Prolapse, Myocarditis, and Marfan Syndrome.
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BICUSPID AORTIC VALVES
WITH AORTIC ROOT DILATATION
There is growing awareness that many patients with
bicuspid aortic valves have disorders of vascular connec-
tive tissue, involving loss of elastic tissue, that may result
in aortic root dilatation even in the absence of hemody-
namically significant AS or AR (17,18). These patients
have a risk of aortic dissection; surgery to repair the aorta
has been recommended for those patients with greatly
enlarged aortic roots (5,18). Recommendations for ath-
letic participation in patients with bicuspid valve disease
and associated aortic root dilatation are based on limited
data, but with the understanding that aortic dissection
can occur in some patients with aortic root diameters less
than 50 mm. The recommendations that follow are for
patients with bicuspid valves and associated aortic root
enlargement. If such patients also have significant AS or
AR, these recommendations should be considered in
concert with those discussed in the present Task Force
for patients with AS or AR. The following recommen-
dations do not pertain to patients with Marfan syndrome,
which are discussed in Task Force 4.
Recommendations:
1. Patients with bicuspid aortic valves with no aortic
root dilatation (less than 40 mm or the equivalent
according to body surface area in children and ado-
lescents) and no significant AS or AR may participate
in all competitive sports.
2. Patients with bicuspid aortic valves and dilated aortic
roots between 40 and 45 mm may participate in low
and moderate static or low and moderate dynamic
competitive sports (classes IA, IB, IIA, and IIB), but
should avoid any sports in these categories that
involve the potential for bodily collision or trauma.
3. Patients with bicuspid aortic valves and dilated aortic
roots greater than 45 mm can participate in only
low-intensity competitive sports (class IA).
TRICUSPID REGURGITATION
Tricuspid regurgitation is most often secondary to right
ventricular (RV) dilation and failure due to pulmonary or
RV hypertension. Other etiologies that may affect athletes
include rheumatic heart disease, tricuspid valve prolapse,
infective endocarditis, congenital anomalies such as
Ebstein’s anomaly, and the sequelae of surgery for congen-
ital heart disease leaving the patient with RV dilatation.
Recommendations here with respect to athletes are for those
with primary TR.
Primary TR leads to RV volume overload with the risk of
subsequent RV failure as well as increased systemic venous
pressure and its consequences. Severity of TR and estima-
tion of right atrial and RV pressures can be determined
noninvasively from physical examination, chest radiograph,
and Doppler echocardiography. Occasionally, right-heart
catheterization is necessary when these measures cannot be
determined noninvasively. There is no evidence that the
athlete with isolated primary TR is placed in jeopardy by
engaging in heavy physical exertion.
Recommendation:
1. Athletes with primary TR, regardless of severity, with
normal RV function in the absence of right atrial
pressure greater than 20 mm Hg or elevation of RV
systolic pressure can engage in all competitive sports.
TRICUSPID STENOSIS
Tricuspid stenosis is for the most part caused by rheumatic
heart disease and is nearly always associated with MS. In
that instance, the patient should be judged according to the
severity of the MS. Isolated tricuspid stenosis is rare. Such
patients should undergo exercise testing at least to the level
anticipated in their sport. If asymptomatic, athletes may
compete in all competitive activities.
MULTIVALVULAR DISEASE
Multivalvular disease occurs in the context of rheumatic
heart disease, myxomatous valvular disease, and infective
endocarditis. The lesions can be diagnosed by physical
examination and Doppler echocardiography. The relative
contribution of each of the lesions may be difficult to assess
noninvasively, and cardiac catheterization and angiocardio-
graphy are frequently necessary to resolve these distinctions.
Recommendation:
1. Multiple lesions of moderate severity may have ad-
ditive physiologic effects. In general, athletes with
significant multiple valvular disease should not par-
ticipate in any competitive sports.
PROSTHETIC HEART VALVES
Several general comments apply to all patients who have
undergone valve replacement. First, although most patients
improve after valve replacement and many become asymp-
tomatic, the long-term mortality after operation is greater
than that of a normal population of similar age. Second, a
transvalvular gradient of varying severity is present in most
patients after valve replacement (5,19). Third, although
hemodynamic variables at rest may be essentially normal
after valve replacement, many patients have an abnormal
response to exercise (20). Finally, after valve replacement
(with few exceptions) patients with mechanical prostheses
require anticoagulant agents, and those with bioprosthetic
valves in sinus rhythm usually do not. In assessing the
athlete’s capacity for physical activity, exercise stress testing
to at least the level of activity performed in the competitive
sport is valuable.
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Effects of exercise. There are insufficient data to determine
whether vigorous repetitive exercise after valve replacement
has any long-lasting effect on ventricular or prosthetic valve
function. The patient should be made aware of these
deficiencies in our knowledge before deciding whether to
participate in competitive athletics. Because mechanical and
most tissue valves have reduced effective valve areas, they
perform best at normal heart rates. Therefore, a sustained
heart rate greater than 120 beats/min might result in
elevated valve gradients and cardiac outputs that are less
than normally expected.
Recommendations:
1. Athletes with a bioprosthetic mitral valve not taking
anticoagulant agents and who have normal valvular
function and normal or near-normal LV function can
participate in low and moderate static and low and
moderate dynamic competitive sports (classes IA, IB,
IIA, and IIB).
2. Athletes with a mechanical or bioprosthetic aortic
valve, with normal valve function and with normal
LV function, can engage in low and moderate static
and low and moderate dynamic competitive sports
(classes IA, IB, and IIA). Athletes participating in
greater than low-intensity competitive sports (class
IA) should undergo exercise testing to at least the
level of activity achieved in competition to evaluate
exercise tolerance and symptomatic and hemody-
namic responses.
3. Independent of other considerations, athletes with a
mechanical or bioprosthetic mitral valve or aortic
valve who are taking anticoagulant agents should not
engage in sports involving the risk of bodily contact
(see Task Force 8: Classification of Sports) or the
danger of trauma.
VALVE REPAIR OR
PERCUTANEOUS MITRAL BALLOON VALVOTOMY
Several general comments apply to athletes who have
undergone valve repair or percutaneous mitral balloon mitral
valvotomy (PMBV). The benefits of surgical mitral valve
repair for MR appear to persist long term, but the effects of
strenuous exercise on repaired mitral valves have not been
studied systematically. After treatment for MS with PMBV
or either closed or open surgical mitral commissurotomy,
the patient should have no disability if there has been no
injury to the left ventricle or development of significant
MR. After aortic valvuloplasty in young patients with
congenital AS, there is the risk of subsequent endocarditis,
AR, or recurrent AS. Athletes should be evaluated for
competitive sports on the basis of their residual hemody-
namic state.
Recommendations:
1. For patients with MS who have undergone successful
PMBV or surgical commissurotomy, recommenda-
tions for participation in competitive sports should
be based on the residual severity of the MS or MR, as
in patients without operation. Capacity to engage in
physical exercise should be evaluated with an exercise
tolerance test at least to the level of anticipated
activity. Patients with LV dysfunction should be
restricted from athletic participation in the same
context as those without operation.
2. Athletes who have undergone mitral valve repair for
MR should not engage in sports involving the risk or
likelihood of bodily contact (see Task Force 8: Clas-
sification of Sports) or possible trauma, which might
disrupt the repair. They can participate in low-
intensity competitive sports (class IA) and, in se-
lected athletes, in low and moderate static and low
and moderate dynamic competitive sports (classes
IA, IB, and IIA).
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HYPERTROPHIC CARDIOMYOPATHY
General considerations. Hypertrophic cardiomyopathy
(HCM) is a relatively common form of genetic heart disease
(0.2%; 1:500 in the general population) (1), and the most
common cause of sudden unexpected cardiac death in young
people, including competitive athletes (2). Sudden death
may occur at any age, but is most common in individuals 30
years of age or less. At present, 12 mutant genes (most
encoding sarcomeric proteins) and over 400 specific muta-
tions in these genes have been implicated in the pathogen-
esis of clinically diagnosed HCM (3).
The disease is characterized by heterogeneous presen-
tation and natural history in which the most consistent
diagnostic feature demonstrated by echocardiography is
otherwise unexplained and usually asymmetric hypertro-
phy associated with a non-dilated left ventricle (LV)
(3–5). Clinical diagnosis of HCM is made by recognition
of the disease phenotype with LV hypertrophy (3,4). In
this regard, a maximal LV end-diastolic wall thickness of
15 mm or more (or on occasion, 13 or 14 mm) is the
absolute dimension generally accepted for the clinical
diagnosis of HCM in an adult athlete (in children, 2 or
more standard deviations from the mean relative to body
surface are; z-score of 2 or more); however, any LV wall
thickness (including normal) is theoretically compatible
with the presence of a mutant HCM gene (3,4). Of note,
individuals of virtually any age (but usually less than 14
years old) harboring a HCM-causing mutant gene may
not manifest LV hypertrophy (3,4).
In a disease such as HCM, extrapolation of risk level
from non-athletes to highly trained competitive athletes is
tenuous. This relates to the unstable electrophysiologic
substrate and propensity for potentially lethal ventricular
tachyarrhythmias in HCM, interacting with the physiologic
stresses inherent in athletic training and competition (i.e.,
alterations in blood volume, hydration, and electrolytes).
Furthermore, no single clinical, morphologic, or electro-
physiologic factor has emerged as the reliable predictor of
risk in HCM (3,4). Therefore, because the panel could not
precisely stratify sudden death risk specifically for all athletes
with HCM, the present recommendations for sports eligi-
bility remain conservative and homogeneous for those
athletes within the diverse HCM clinical spectrum.
Given the inability to precisely stratify risk on clinical
grounds in individual young patients with HCM, a broad
recommendation to exclude such individuals from compet-
itive sports will, by definition, deny participation to some
unnecessarily. However, given the frequency with which
HCM is associated with sudden death in young athletes (2),
and recent data showing that athletic activity per se is
associated with higher risk in those with underlying cardio-
vascular abnormalities (6), the present recommendations are
viewed as prudent. That is, the goal is to encompass all
preventable sudden deaths in young persons with HCM,
while acknowledging that other athletes who may not be
destined for sudden death will also be subjected to the same
recommendations.
Preclinical diagnosis. With the availability of preclinical
genetic diagnosis, a relatively small number of youthful
family members have been identified as affected by a
HCM-causing mutant gene solely on the basis of laboratory
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